{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:56:02Z","timestamp":1781938562407,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02306-0","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:12:10Z","timestamp":1774494730000},"page":"943-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Depemokimab: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"12","key":"2306_CR1","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312\u20139.","journal-title":"Allergy"},{"issue":"3","key":"2306_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jaci.2021.10.029","volume":"149","author":"GK Scadding","year":"2022","unstructured":"Scadding GK, Scadding GW. Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP). J Allergy Clin Immunol. 2022;149(3):895\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"2306_CR3","unstructured":"Medicines and Healthcare products Regulatory Agency. UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps [media release]. 15 Dec 2025. https:\/\/www.gov.uk\/."},{"key":"2306_CR4","unstructured":"GSK. Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps [media release]. 15 Dec 2025. https:\/\/www.gsk.com."},{"key":"2306_CR5","unstructured":"GSK. Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma [media release]. 16 Dec 2025. https:\/\/www.gsk.com."},{"key":"2306_CR6","unstructured":"GSK. Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps [media release]. 6 Jan 2026. https:\/\/www.gsk.com\/."},{"key":"2306_CR7","unstructured":"European Medicines Agency. Exdensur (depemokimab) CHMP Summary of opinion [media release].  11 Dec 2025. https:\/\/www.ema.europa.eu\/."},{"key":"2306_CR8","unstructured":"GSK. GSK drug pipeline for respiratory indications. 2025. https:\/\/gskusmedicalaffairs.com\/respiratory\/pipeline\/. Accessed 25 Feb 2026."},{"key":"2306_CR9","unstructured":"GSK. EXDENSUR (depemokimab): UK summary of product characteristics. 2025."},{"key":"2306_CR10","unstructured":"GSK. EXDENSUR (depemokimab-ulaa): US prescribing information. 2025. https:\/\/gskpro.com\/. Accessed 25 Feb 2026."},{"key":"2306_CR11","unstructured":"GSK. EXDENSUR (depemokimab): Japanese prescribing information [translated]. 2026."},{"key":"2306_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e44247","author":"M Orecchia","year":"2026","unstructured":"Orecchia M, Welbeck K, Dexter J, et al. Generation and preclinical assessment of depemokimab, an enhanced IL-5 antagonist monoclonal antibody. Heliyon. 2026. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e44247.","journal-title":"Heliyon"},{"key":"2306_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70183","author":"C Zecchin","year":"2026","unstructured":"Zecchin C, Schalkwijk S, Pouliquen IJ, et al. Straight to phase III: model-informed approach speeds depemokimab clinical development in interleukin-5-driven diseases. Clin Pharmacol Ther. 2026. https:\/\/doi.org\/10.1002\/cpt.70183.","journal-title":"Clin Pharmacol Ther"},{"issue":"Abstracts","key":"2306_CR14","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A2502","volume":"211","author":"P Lukka","year":"2025","unstructured":"Lukka P, Penland R, Brekkan A, et al. Model-based comparison of the pharmacokinetic\/pharmacodynamic and eosinophilic response of benralizumab versus depemokimab at 12 weeks. Am J Respir Crit Care Med. 2025;211(Abstracts):A2502.","journal-title":"Am J Respir Crit Care Med"},{"issue":"24","key":"2306_CR15","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024;391(24):2337\u201349.","journal-title":"N Engl J Med"},{"key":"2306_CR16","doi-asserted-by":"crossref","unstructured":"Desrosiers M, Schalkwijk S, Edwards D, et al. Pharmacokinetics and pharmacodynamics of twice-yearly depemokimab in the randomized, double-blind, placebo-controlled parallel phase III ANCHOR-1\/2 trials [abstract no. L80]. J Allergy Clin Immunol. 2025.","DOI":"10.1016\/j.jaci.2024.12.1054"},{"issue":"3","key":"2306_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/cpdd.1506","volume":"14","author":"S Schalkwijk","year":"2025","unstructured":"Schalkwijk S, Zecchin C, Sen A, et al. Pharmacokinetics of depemokimab delivered by safety syringe device or autoinjector in healthy adults: a phase 1, single-dose study. Clin Pharmacol Drug Dev. 2025;14(3):190\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2306_CR18","doi-asserted-by":"crossref","unstructured":"Wechsler M, Pfeffer P, Bernstein D, et al. Long-term safety and efficacy of depemokimab in patients with type 2 asthma: a single-arm, open-label extension study (AGILE) [abstract no. DV-005587]. Am Acad Allergy Asthma Immunol. 2026.","DOI":"10.1016\/j.jaci.2025.12.831"},{"issue":"10482","key":"2306_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert P, Desrosiers M, Cornet M, et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet. 2025;405(10482):911\u201326.","journal-title":"Lancet"},{"issue":"2","key":"2306_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12325-025-03457-4","volume":"43","author":"DJ Jackson","year":"2026","unstructured":"Jackson DJ, Bourdin A, Blackorby A, et al. Safety and tolerability of twice-yearly depemokimab in patients with asthma and chronic rhinosinusitis with nasal polyps: pooled results from SWIFT-1\/-2 and ANCHOR-1\/-2. Adv Ther. 2026;43(2):880\u201397.","journal-title":"Adv Ther"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02306-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02306-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02306-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:39:58Z","timestamp":1778855998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02306-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02306-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}